Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Ciba Vision's Livostin

Executive Summary

Ciba Vision's Livostin: Promotion of Livostin (levocabastine ophthalmic suspension, .05%) announcing removal of labeling restricting use to two weeks will begin before start of fall allergy season through ads in professional journals, Ciba Vision says. FDA approved SNDA 20-219/S-003 June 10 for Livostin, which is indicated for relief of seasonal allergic conjunctivitis symptoms. Approval also changes incidence of "mild, transient stinging and burning" from 15% to 29% in adverse reactions section of labeling...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028776

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel